

# **Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/RDC34CDA6ECEN.html>

Date: July 2018

Pages: 43

Price: US\$ 3,500.00 (Single User License)

ID: RDC34CDA6ECEN

## **Abstracts**

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2018

### **SUMMARY**

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

The latest report Rho Associated Protein Kinase 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber

and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A.

It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. The molecules developed by companies in Phase I and Preclinical stages are 1 and 8 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders and Ophthalmology which include indications Inflammation, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Contact Dermatitis, Fibrosis, Glaucoma, Hypersensitivity, Hypertension, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Kidney Fibrosis, Neurodegenerative Diseases, Pain, Rheumatoid Arthritis and Solid Tumor.

Furthermore, this report also reviews key players involved in Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1)

The report reviews Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics under development by

companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1

or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Overview

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

AbbVie Inc

Astex Pharmaceuticals Inc

BioAxone BioSciences Inc

Kadmon Corp LLC

Pfizer Inc

Redx Pharma Plc

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Drug Profiles

AMA-0825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-3485 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-13148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-1076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-00974 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KL-01045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Rho-Associated Kinase I for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROCK1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Dormant Products

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Discontinued Products

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Jun 18, 2013: Moffitt Cancer Center Announces Strategic Partnership with Advinus Therapeutics

Jan 17, 2013: Cancer Research UK And Cancer Research Technology Launches Phase I Clinical Trial With AT13148 To Treat Several Cancer Types

Jan 16, 2013: Astex Pharma Announces Cancer Research UK And Cancer Research Technology Initiate AT13148 Clinical Trial To Treat Several Cancer Types

Jul 10, 2012: Experimental Drug Could Treat Different Cancers, New Research Says

Oct 18, 2007: Astex Drug Candidates To Be Featured At The 2007 AACR-NCI-EORTC International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by AbbVie Inc, H2 2018

Pipeline by Astex Pharmaceuticals Inc, H2 2018

Pipeline by BioAxone BioSciences Inc, H2 2018

Pipeline by Kadmon Corp LLC, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Redx Pharma Plc, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

### COMPANIES MENTIONED

AbbVie Inc

Astex Pharmaceuticals Inc

BioAxone BioSciences Inc

Kadmon Corp LLC

Pfizer Inc

Redx Pharma Plc

## I would like to order

Product name: Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/RDC34CDA6ECEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDC34CDA6ECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970